SAN FRANCISCO, CA -- (Marketwired) -- 07/17/14 -- Having a chronic disease like diabetes engenders a sense of isolation that hasn't been adequately addressed by technology until now. With Dario, LabStyle Innovations Corp. (OTCQB: DRIO) has created a device that not only provides vital medical information to a diabetic patient in real time, but also connects that patient to a community of care providers, family, and online resources. In this interview with The Life Sciences Report, LabStyle President and CEO Erez Raphael describes how the Dario software platform could provide sufferers of other chronic diseases with the benefits of real-time data and community as well.
The Life Sciences Report: Your first marketed brand is Dario. Could you please describe this device?
Erez Raphael: Dario is a solution for diabetes. In fact, the name Dario stands for "diabetes all in one." The "r" is just for fun.
In general, we provide a solution for diabetes patients using a smartphone, software and the cloud. The Dario device turns a smartphone into a glucose meter and, with the software from the Dario App, whether it is downloaded for iOS or Android or cloud-based services, we can provide a treatment overview.
The understanding we had from the market, and from our understanding of diabetes itself, was that in addition to a device or tool, patients needed other elements related to empowerment, information and overall support for their treatment regimens. By making a glucose meter look like a gadget, smaller and integrated into a smartphone...
Continue reading this interview with Erez Raphael: Dial In on Diabetes Solutions with LabStyle Innovations Corp.'s Dario
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.
LabStyle Innovations paid The Life Sciences Report to conduct, produce and distribute the interview. LabStyle Innovations had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of LabStyle Innovations and not Streetwise Reports or The Life Sciences Report or its officers.